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One of the most challenging aspects of obesity is its link to “metabolic syndrome,” 
when abdominal obesity is accompanied by high fasting blood glucose, low levels of 
high-density lipoprotein cholesterol, high levels of triglycerides, and elevated blood 
pressure. With rising obesity rates, metabolic syndrome is likely to become more 
common in the years ahead (1). Although progress has been made in identifying this 
syndrome’s individual components, their interplay across several organ systems is not 
well understood; that is, the near-linear relationship between body mass index and 
blood pressure. Obesity is often recognized as a predictor of treatment-resistant 
hypertension (2). One of the main endocrine pathways that has been implicated 
involves natriuretic peptides (3). Natriuretic peptides exert their antihypertensive 
effects predominantly by inducing natriuresis but have additional effects beyond blood 
pressure regulation. For example, an antihypertrophic effect, independent of blood 
pressure, was observed in the heart (4). Other reports demonstrate the ability of atrial 
natriuretic peptide (ANP) to promote lipolysis (5) and activate the brown fat 
thermogenic program (6). Notably, levels of natriuretic peptides are lower in obese 
subjects and patients with type 2 diabetes (7). 
Genetic studies demonstrated that the single nucleotide polymorphism rs5068 (A/G) 
is most strongly associated with plasma ANP levels. Carriers of the minor G allele are 
less obese, have a lower risk of hypertension, and a decreased incidence of 
cardiovascular events (8). In this issue of the Journal, Arora et al. (9) expand upon 
their previous finding that the variant rs5068 (A/G) influences ANP 
production (10). NPPA, which encodes for ANP, is a target of micro ribonucleic acid 
(miRNA)-425 (miR-425). miR-425 is predicted to bind the sequence spanning rs5068 
for the A, but not the G allele (Figure 1). Overexpression of miR-425 in human 
cardiomyocytes derived from induced pluripotent stem cells reduced NPPAmessenger 
RNA and N-terminal (NT)-proANP protein levels (10). 
In the present study, Arora et al. (9) explored miR-425 as a link between glycemia and 
ANP expression, thereby providing a potential explanation for lower NT-proANP 
plasma levels after food consumption (11). The authors demonstrated that: 1) a 
carbohydrate challenge lowered plasma ANP, but not brain natriuretic peptide; 2) high 
glucose increased miR-425 and decreased NPPA expression in human 
cardiomyocytes derived from embryonic stem cells; 3) a glucose stimulus enhanced 
the transcription downstream of the miR-425 promoter in HepG2 cells, a human liver 
carcinoma cell line; and 4) miR-425 expression was nuclear factor kappa B (NF-κB)–
dependent in H9c2 cells, a rat cardiomyoblast cell line (Figure 1). Importantly, 
the human, but not the rodent, NPPA gene was a target of miR-425. By using 
transgenic mice carrying the human NPPA gene (NPPAtg/+ mice), the authors provided 
in vivo evidence for an inverse association of miR-425 and human NPPA expression 
in the right ventricle after glucose administration. 
Key questions remain unanswered: Can inhibition of endogenous miR-425 attenuate 
the glucose-induced decrease in NPPA transcription or are miR-425–independent 
mechanisms responsible for regulating NPPA levels upon glucose stimulation? The 
latter could have been addressed by determining whether the endogenous 
mouse NPPA levels were unchanged after the glucose gavage. Moreover, miRNA 
targets can change depending on the cell context. Does inhibition of endogenous miR-
425 result in a similar rise of ANP secretion in all cardiomyocyte-like cells? It remains 
unclear whether miR-425 is associated with cardiometabolic phenotypes in mice as 
observed by targeting other miRNAs (12). No data were included on metabolic 
parameters, blood pressure, and cardiac function of NPPAtg/+mice. 
A direct effect of endogenous miR-425 on ANP expression levels should have been 
confirmed in vitro and in vivo, to rule out a possible contribution by other miRNAs. For 
example, miR-103 and -107 are expressed in the heart (13), and are predicted to 
target the human NPPA gene. Expression levels of miR-103 and 107 are increased in 
livers of obese mice and regulate insulin sensitivity (14). A 20% to 30% increase of 
miR-425 expression was observed in the right atria and the right ventricles 
after NPPAtg/+ mice were gavaged with 2 g/kg glucose (9). The authors inferred that 
the concurring decrease of human NPPAexpression in the right ventricle was the result 
of increased miR-425 levels, but presented no direct evidence that this modest change 
of miR-425 can account for the effects of glucose administration on NPPA expression. 
Unlike ANP that is predominantly expressed in the atria, miR-425 expression was 
observed in several tissues, including liver and pancreas. MiR-425 expression levels 
in the myocardium are relatively low (15) and similar in atrial and ventricular 
tissues (10). The marked increase in ANP expression in cardiac tissue of heart failure 
(HF) patients (15) was associated with a compensatory rise in miR-425 levels 
(Figure 2). Unloading by a left ventricular assist device reduced ANP levels 
in nonischemic HF patients with a corresponding reduction in miR-425 expression. 
Thus, in patients with advanced HF, miR-425–independent mechanisms appear to be 
at work, and miR-425 might fine tune, rather than determine, levels of ANP expression. 
One of the recent landmark clinical trials in cardiovascular disease evaluated a 
neprilysin inhibitor, targeting the endopeptidase that degrades the natriuretic peptides 
(among others), which was chemically linked to an angiotensin receptor blocker (16). 
The impressive reduction of hospitalization for HF, as well as death from 
cardiovascular causes, might be explained, at least in part, by increasing ANP levels 
in the intervention group. Given this emerging new gold standard in clinical care, it is 
questionable whether miR-425 inhibitors would have therapeutic potential for raising 
ANP (10). Pharmacological modulation of miRNA expression can be successfully 
achieved (17). However, miRNA therapeutics face major challenges in that single 
base changes may profoundly affect toxicology, and off-target effects can occur due 
to the ubiquitous expression of most miRNAs. Also, there are difficulties in establishing 
the correct dosing regimen, demonstrating target engagement, and ensuring efficient 
delivery, in particular to the heart. Oligonucleotides tend to accumulate in the liver and 
the kidney. This build-up could become a concern during prolonged treatment for 
chronic conditions, such as metabolic syndrome. 
In summary, Arora et al. (9) presented evidence for a mechanism whereby glucose 
intake induced miR-425 expression, which in turn decreased ANP levels, potentially 
contributing to hypertension and other deleterious effects in cardiometabolic disease. 
Although a definitive pathophysiological link between miR-425, obesity, diabetes, and 
ANP levels is not yet established, this study does add to the compelling evidence that 
miRNAs are part of important regulatory mechanisms in cardiometabolic diseases that 
merit further investigation (18). 
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FIGURE LEGENDS 
 
Figure 1. Association of miR-425 With ANP 
(A) In the base pairing between microribonucleic acid 425 (miR-425) and the 3′ 
untranslated region (3′ UTR) of human NPPA, the red box indicates the seed 
sequence (position 2 to 8). Yellow = variants of rs5068. (B) The in vitro and in vivo 
effects as observed in the study by Arora et al. (9). DNA = deoxyribonucleic acid; 
hESC-CM = human embryonic stem cell–derived cardiomyocyte; NF = nuclear factor; 
NT-proANP = N-terminal pro-atrial natriuretic peptide; RA = right atrium; RNA = 
ribonucleic acid; RV = right ventricle. 
 
Figure 2. MiR-425 and ANP Levels in Cardiac Tissue 
Atrial natriuretic peptide (ANP) (A) and microribonucleic acid 425 (miR-
425) (B) expression levels were determined by deep RNA sequencing of cardiac 
tissue from nonfailing (NF) patients, from patients with ischemic cardiomyopathy 
(ICM), and from patients with nonischemic cardiomyopathy (NICM) pre- and post-left 
ventricular assist device (LVAD) implantation, respectively (15). *p < 0.05, **p < 0.01 
compared with NF patients. Reprinted with permission of Wolters Kluwer Health, Inc. 
 
hNPPAtg/+ mice 
IN VITRO 
hESC-CM HepG2 H9c2 
Glucose 
NPPA miR-425 
Transfection   
Plasmids with 
NF-κB subunits 
(p50, p65) 
Glucose 
miR-425 
Glucose 
IN VIVO HUMANS 
NF-κB 
miR-425 Causality? 
hNPPA 
in RV 
miR-425 
in RA/RV 
Causality? 
? 
Plasma 
Glucose 
Nt-
proANP 
miR-425 
Figure 1 
010
20
30
Re
la
tiv
e 
Tr
an
sc
rip
t E
xp
re
ss
io
n 
ANF 
miR-425-5p 
Re
ad
 C
ou
nt
s 
* * 
** 
* 
* 
0
20
40
60
80
Figure 2 
